The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis.

MLA

Engels, C., et al. “The Prognostic and Predictive Value of Tregs and Tumor Immune Subtypes in Postmenopausal, Hormone Receptor-Positive Breast Cancer Patients Treated with Adjuvant Endocrine Therapy: A Dutch TEAM Study Analysis.” Breast Cancer Research & Treatment, vol. 149, no. 3, Feb. 2015, pp. 587–96. EBSCOhost, https://doi.org/10.1007/s10549-015-3269-7.

APA

Engels, C., Charehbili, A., Velde, C., Bastiaannet, E., Sajet, A., Putter, H., Vliet, E., Vlierberghe, R., Smit, V., Bartlett, J., Seynaeve, C., Liefers, G., & Kuppen, P. (2015). The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis. Breast Cancer Research & Treatment, 149(3), 587–596. https://doi.org/10.1007/s10549-015-3269-7

Chicago

Engels, C., A. Charehbili, C. Velde, E. Bastiaannet, A. Sajet, H. Putter, E. Vliet, et al. 2015. “The Prognostic and Predictive Value of Tregs and Tumor Immune Subtypes in Postmenopausal, Hormone Receptor-Positive Breast Cancer Patients Treated with Adjuvant Endocrine Therapy: A Dutch TEAM Study Analysis.” Breast Cancer Research & Treatment 149 (3): 587–96. doi:10.1007/s10549-015-3269-7.